Amit Kumar Tiwari
Senior Patent Associate
Also affiliated: Jain University (2017); Birla Institute of Technology, Mesra (2021–2024); Government Medical College (2020); Motilal Nehru National Institute of Technology (2024); University of Allahabad (2024); Indian Veterinary Research Institute (2001–2022); Northern Alberta Institute of Technology (2025); Rani Durgavati University (2025); Symbiosis International University (2021–2025); Darbhanga Medical College and Hospital (2020–2021); Shyam Shah Medical College (2024); Diabetes Care and Research Foundation (2024); Institute of Post Graduate Medical Education and Research (2020); Era's Lucknow Medical College and Hospital (2020); Pacific Dental College and Hospital (2016); D.Y. Patil University (2024); Indian Agricultural Research Institute (2023); Bose (United States) (2020); Central University of Rajasthan (2013); Newcastle University (2015–2018); Vellore Institute of Technology University (2024); University of Toledo (2017); Gyan Vihar University (2025)
COP | College of Pharmacy
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Amit Kumar Tiwari's research focuses on drug resistance mechanisms in cancer cells, particularly involving ATP-binding cassette (ABC) transporters. His work has investigated how specific compounds, such as Lapatinib and Apatinib, can reverse multidrug resistance by inhibiting the function of these efflux pumps. His publications explore the role of ABC transporters in cancer chemotherapy and genetic diseases, as well as broader strategies for targeted drug discovery in oncology.
Beyond his primary research interests, Dr. Tiwari's academic background includes extensive training in chemistry, medicinal chemistry, cheminformatics, and patent law. He holds postgraduate diplomas in these fields and is a certified intellectual property professional. His expertise also extends to competitive intelligence, acquisition, and innovation management. He has published on topics ranging from amide bond bioisosteres and alternatives to biological skin in permeation studies to the review of BCR-ABL tyrosine kinase inhibitors.
Dr. Tiwari has an h-index of 12 and has published 129 works with 828 citations. He is recognized as a highly cited researcher and leads a research group at the University of Arkansas for Medical Sciences, collaborating with several colleagues within the institution.
Metrics
- h-index: 12
- Publications: 129
- Citations: 828
Positions
-
Senior Patent Associate 2022–presentR.K. Dewan and Co. Patent Department ORCID
-
Senior Patent Associate publications 2025University of Arkansas for Medical Sciences COP | College of Pharmacy Institutional directory
-
Professor and Head – Intellectual Property 2019–2022Symbiosis International University Symbiosis Centre for Research and Innovation (SCRI) ORCID
-
Head (Intellectual Property & Scientific Database Operations) 2012–2019Hikal Limited Research & Development ORCID
-
Location Head (Intellectual Property Management – API & Formulations) 2010–2012Micro Labs Limited Research & Development ORCID
-
Head (Intellectual Property Management – API & Formulations) 2008–2010Nectar Lifesciences Limited Research & Development ORCID
-
Research Associate 2005–2008Orchid Chemicals & Pharmaceuticals Limited Research & Development ORCID
-
Research Associate (Intellectual Property and Information Management) 2004–2005Jubilant Organosys Limited Research & Development ORCID
-
R & D Chemist 2002–2003Medicorp Technologies India Limited Research & Development (Organic Synthesis, Chemical Information & Patents) ORCID
-
Assistant Professor 2000–2001Unique College Biochemistry ORCID
Selected Publications
-
Stability of Ketamine-Xylazine-Butorphanol formulation to establish an evidence-based beyond-use date (2026)
-
The hidden hand of endoplasmic reticulum stress in anticancer drug resistance (2025)
-
Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities (2025)
-
Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer (2025)
-
Dapagliflozin Reverses LPS ‐Induced Depressive–Like Behavior in Mice via Modulation of Glutamate and NF ‐ κB (2025)
-
An Update on Novel Drug Delivery Systems for the Management of Glaucoma (2025)
-
Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer (2025)
-
Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery (2025)
-
Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects (2025)
-
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy (2025)
-
Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer (2024)
-
Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery (2024)
-
Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells (2024)
-
Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives (2024)
-
Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants (2024)
Research Interests
Dr. Tiwari is an Associate Dean of Research & Graduate Studies and a Professor of Pharmaceutical Sciences in the College of Pharmacy at University of Arkansas for Medical Sciences, Arkansas. He is a seasoned pharmacologist, a board-certified toxicologist and also leads a funded ?Cancer and Systems Therapeutics (CAST) program. He has been widely cited and has published, over 240 peer reviewed publications, patents and book chapters. CAST team is involved in a) developing effective, safe, and targeted anticancer molecules against multidrug-resistant cancers; b) designing, synthesizing and characterizing non-conventional forms of cell death inducers. CAST team has discovered first-in-class, safe agents that activate necroptosis, methuosis, methuophagy, ferroptosis, entosis, and immunogenic cell death, sensitizing resistant cancers to immuno- and radiotherapies. Integrating biomimetic microfluidics, high-content imaging, and AI-driven analytics, his group develops predictive tools to understand and overcome chemotherapy failure. In parallel, they are advancing patented macropinocytosis-based delivery platforms that enhance intracellular transport of siRNAs and proteins. Supported by multiple federal and foundation grants, issued patents, and international collaborations, Dr. Tiwari’s translational program bridges preclinical innovation with therapeutic impact.; Drug Discovery; Drug Resistance; Non Apoptotic Cell Death; Formulations, Drug; Drug Delivery Systems; Intellectual Properties
Grants & Funding
As listed on this researcher's institutional profile.
- Development of Novel Inducers of Non-Apoptotic Cell Death to Target TNBC US Department of Defense Principal Investigator
- High-throughput high-resolution microscopy for phenotypic drug discovery applications NIH/Nat. Inst. of Biomedical Imaging & Bioengineering via University of Toledo Principal Investigator
- ABI A. Tiwari Startup FY26 Y3 State of Arkansas Principal Investigator
Collaboration Network
Top Collaborators
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- The hidden hand of endoplasmic reticulum stress in anticancer drug resistance
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
Showing 5 of 9 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 8 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 8 shared publications
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Showing 5 of 7 shared publications
- Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
- Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
- Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A
- Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer
- Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
Showing 5 of 7 shared publications
- Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
- Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer
- The hidden hand of endoplasmic reticulum stress in anticancer drug resistance
- Dapagliflozin Reverses LPS ‐Induced Depressive–Like Behavior in Mice via Modulation of Glutamate and NF ‐ κB
- Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells
Showing 5 of 6 shared publications
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
- The Role of Cytokines in Activation of Tumour-promoting Pathways andEmergence of Cancer Drug Resistance
- Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities
- Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
- Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer
- Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
- Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A
- Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma
- Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer
- Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
- Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells
- Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
- Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
- The hidden hand of endoplasmic reticulum stress in anticancer drug resistance
- Biomimetic on-chip assay reveals the anti-metastatic potential of a novel thienopyrimidine compound in triple-negative breast cancer cell lines
- Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells
- Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
- Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer
- Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives
- The Role of Cytokines in Activation of Tumour-promoting Pathways andEmergence of Cancer Drug Resistance
Similar Researchers
Based on overlapping research topics